Switch to:
Also traded in: Argentina, Brazil, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 0.72
BMY's Cash-to-Debt is ranked lower than
63% of the 799 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.05 vs. BMY: 0.72 )
Ranked among companies with meaningful Cash-to-Debt only.
BMY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.32  Med: 1.06 Max: N/A
Current: 0.72
Equity-to-Asset 0.44
BMY's Equity-to-Asset is ranked lower than
76% of the 731 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. BMY: 0.44 )
Ranked among companies with meaningful Equity-to-Asset only.
BMY' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.33  Med: 0.46 Max: 0.64
Current: 0.44
0.33
0.64
Interest Coverage 28.42
BMY's Interest Coverage is ranked lower than
61% of the 632 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 112.31 vs. BMY: 28.42 )
Ranked among companies with meaningful Interest Coverage only.
BMY' s Interest Coverage Range Over the Past 10 Years
Min: 8.03  Med: 15.49 Max: 45.84
Current: 28.42
8.03
45.84
Piotroski F-Score: 6
Altman Z-Score: 5.83
Beneish M-Score: -2.46
WACC vs ROIC
7.78%
22.08%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 24.06
BMY's Operating Margin % is ranked higher than
86% of the 758 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.95 vs. BMY: 24.06 )
Ranked among companies with meaningful Operating Margin % only.
BMY' s Operating Margin % Range Over the Past 10 Years
Min: 11.41  Med: 21.37 Max: 31.29
Current: 24.06
11.41
31.29
Net Margin % 24.22
BMY's Net Margin % is ranked higher than
91% of the 759 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.06 vs. BMY: 24.22 )
Ranked among companies with meaningful Net Margin % only.
BMY' s Net Margin % Range Over the Past 10 Years
Min: 9.45  Med: 15.78 Max: 56.42
Current: 24.22
9.45
56.42
ROE % 32.02
BMY's ROE % is ranked higher than
91% of the 780 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.91 vs. BMY: 32.02 )
Ranked among companies with meaningful ROE % only.
BMY' s ROE % Range Over the Past 10 Years
Min: 10.75  Med: 20.69 Max: 78.36
Current: 32.02
10.75
78.36
ROA % 14.65
BMY's ROA % is ranked higher than
87% of the 805 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.71 vs. BMY: 14.65 )
Ranked among companies with meaningful ROA % only.
BMY' s ROA % Range Over the Past 10 Years
Min: 4.78  Med: 9.18 Max: 35.08
Current: 14.65
4.78
35.08
ROC (Joel Greenblatt) % 132.72
BMY's ROC (Joel Greenblatt) % is ranked higher than
95% of the 793 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.48 vs. BMY: 132.72 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BMY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 45.71  Med: 72.1 Max: 155.17
Current: 132.72
45.71
155.17
3-Year Revenue Growth Rate 5.50
BMY's 3-Year Revenue Growth Rate is ranked higher than
52% of the 634 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.10 vs. BMY: 5.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
BMY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -8.4  Med: 3.1 Max: 11.8
Current: 5.5
-8.4
11.8
3-Year EBITDA Growth Rate 18.40
BMY's 3-Year EBITDA Growth Rate is ranked higher than
68% of the 601 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.90 vs. BMY: 18.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
BMY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -26  Med: 7.6 Max: 22.1
Current: 18.4
-26
22.1
3-Year EPS without NRI Growth Rate 19.80
BMY's 3-Year EPS without NRI Growth Rate is ranked higher than
71% of the 576 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.60 vs. BMY: 19.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
BMY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -22.9  Med: 5.9 Max: 30.7
Current: 19.8
-22.9
30.7
GuruFocus has detected 4 Warning Signs with Bristol-Myers Squibb Company $BMY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BMY's 30-Y Financials

Financials (Next Earnings Date: 2017-07-27)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

BMY Guru Trades in Q3 2016

Julian Robertson 400,800 sh (New)
Joel Greenblatt 87,321 sh (New)
Jim Simons 4,740,200 sh (+782.72%)
Paul Tudor Jones 116,887 sh (+747.01%)
Ray Dalio 390,577 sh (+109.48%)
Mairs and Power 330,822 sh (+15.77%)
Vanguard Health Care Fund 48,804,797 sh (+7.84%)
Ken Fisher 650,332 sh (+0.34%)
First Eagle Investment 11,529 sh (unchged)
Kahn Brothers 28,583 sh (unchged)
Tom Gayner 10,000 sh (unchged)
Keeley Asset Management Corp Sold Out
Jeremy Grantham Sold Out
Steven Cohen Sold Out
Dodge & Cox 71,958 sh (-0.28%)
Ronald Muhlenkamp 180,316 sh (-0.56%)
Murray Stahl 56,324 sh (-4.17%)
Jeff Auxier 4,693 sh (-6.01%)
T Rowe Price Equity Income Fund 3,100,000 sh (-6.77%)
Mario Gabelli 556,927 sh (-10.12%)
Signature Select Canadian Fund 160,450 sh (-35.90%)
Pioneer Investments 110,604 sh (-44.44%)
Ron Baron 47,479 sh (-58.69%)
Eaton Vance Worldwide Health Sciences Fund 955,887 sh (-13.76%)
» More
Q4 2016

BMY Guru Trades in Q4 2016

David Tepper 375,000 sh (New)
Jeremy Grantham 3,500 sh (New)
Manning & Napier Advisors, Inc 3,060,280 sh (New)
Jana Partners 3,872,261 sh (New)
Dodge & Cox 22,532,761 sh (+31213.77%)
Vanguard Health Care Fund 51,340,697 sh (+5.20%)
Mairs and Power 340,822 sh (+3.02%)
T Rowe Price Equity Income Fund 3,125,000 sh (+0.81%)
Ken Fisher 653,730 sh (+0.52%)
First Eagle Investment 11,529 sh (unchged)
Kahn Brothers 28,583 sh (unchged)
Tom Gayner 10,000 sh (unchged)
Jeff Auxier 4,693 sh (unchged)
Julian Robertson Sold Out
Ron Baron Sold Out
Joel Greenblatt Sold Out
Ray Dalio Sold Out
Pioneer Investments 110,498 sh (-0.10%)
Ronald Muhlenkamp 178,961 sh (-0.75%)
Mario Gabelli 523,672 sh (-5.97%)
Murray Stahl 52,592 sh (-6.63%)
Paul Tudor Jones 23,777 sh (-79.66%)
Jim Simons 597,000 sh (-87.41%)
Eaton Vance Worldwide Health Sciences Fund 721,457 sh (-24.52%)
» More
Q1 2017

BMY Guru Trades in Q1 2017

Joel Greenblatt 10,061 sh (New)
PRIMECAP Management 1,772,900 sh (New)
Steven Cohen 152,500 sh (New)
Ray Dalio 96,670 sh (New)
Frank Sands 17,124 sh (New)
Jim Simons 6,468,000 sh (+983.42%)
Jeff Auxier 7,393 sh (+57.53%)
Dodge & Cox 29,120,190 sh (+29.23%)
T Rowe Price Equity Income Fund 3,750,000 sh (+20.00%)
Manning & Napier Advisors, Inc 3,236,578 sh (+5.76%)
Vanguard Health Care Fund 52,795,017 sh (+2.83%)
Ken Fisher 666,264 sh (+1.92%)
Mairs and Power 344,280 sh (+1.01%)
First Eagle Investment 11,529 sh (unchged)
Kahn Brothers 28,583 sh (unchged)
Tom Gayner 10,000 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 721,457 sh (unchged)
David Tepper Sold Out
Jeremy Grantham Sold Out
Ronald Muhlenkamp 178,201 sh (-0.42%)
Pioneer Investments 108,348 sh (-1.95%)
Mario Gabelli 513,047 sh (-2.03%)
Murray Stahl 48,607 sh (-7.58%)
Paul Tudor Jones 21,701 sh (-8.73%)
Signature Select Canadian Fund 118,750 sh (-25.99%)
Jana Partners 716,389 sh (-81.50%)
» More
Q2 2017

BMY Guru Trades in Q2 2017

Spiros Segalas 8,100,829 sh (+36.63%)
T Rowe Price Equity Income Fund 3,670,300 sh (-2.13%)
Ken Fisher 507,027 sh (-23.90%)
Manning & Napier Advisors, Inc 2,034,602 sh (-37.14%)
» More
» Details

Insider Trades

Latest Guru Trades with BMY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Bristol-Myers Squibb Company

SymbolPriceYieldDescription
BMYMP965.000.21$2.00 Convertible Preferred Stock

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:NYSE:LLY, NYSE:ABBV, NYSE:MRK, NAS:AERI, AMEX:TXMD, NAS:RTRX, NAS:RMTI, NAS:ZGNX, AMEX:NNVC, NAS:ALIM, NAS:PRPH, NAS:TNXP, NAS:IMNP, AMEX:AXN, OTCPK:INNV, NAS:ALQA, OTCPK:INBP, OTCPK:ECTE, OTCPK:ENZB, NYSE:PFE » details
Traded in other countries:BMY.Argentina, BMYB34.Brazil, BRM.Germany, BMY.Mexico, BMY.Switzerland, 0R1F.UK,
Headquarter Location:USA
Bristol-Myers Squibb Co is engaged in discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceuticals and nutritional products. The company operates in two segments namely Pharmaceuticals and Nutritionals.

Bristol-Myers Squibb discovers, develops, and markets drugs for various indications, such as cardiovascular and infectious diseases, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is leading in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded drugs.

Guru Investment Theses on Bristol-Myers Squibb Company

Baron Funds' Fifth Avenue Growth Fund Comments on Bristol-Myers Squibb Company - Feb 13, 2017

Bristol-Myers Squibb Company (NYSE:BMY) is a leading developer in Immuno-Oncology, the new wave of therapeutics aimed at displacing chemotherapeutics in cancer care with both improved efficacy (measured via survival outcomes) and safety profiles. While the class as a whole represents a success for society, the race for class dominance is heated and has proven to be difficult to predict. Coming into mid-2016, Bristol was the clear leader. The company squandered this lead in July when a widely anticipated clinical trial whose outcome was expected to read out positively, failed. While few question the drug’s efficacy, statistics and poor clinical trial design submarined Bristol and allowed competitor Merck to take the pole position commercially. Given the dire need for this patient population, the FDA granted Merck a pathway to market by the first half of this year that will give Merck at least a one year commercial advantage in time to market versus its competition. As a result, we decided to exit our investment in Bristol. While Merck has become the consensus leader, we think that their combination employs the wrong science approach and that Bristol is one of two players (AstraZeneca, the other) that will have an opportunity to ultimately come out on top given its strategy of combining two immune-therapeutics. We intend to follow the situation closely while looking for a more appropriate time to potentially get back into the investment.



From Baron Funds' Fifth Avenue Growth Fund fourth quarter 2016 commentary.



Check out Ron Baron latest stock trades

Dodge & Cox Comments on Bristol-Myers Squibb - Feb 01, 2017

Once a diversified pharmaceutical company facing significant patent expirations (a “cliff”), Bristol-Myers (NYSE:BMY) has transitioned into a focused biopharmaceutical company that is positioned to grow. Many of its competitors responded to their patent cliffs by expanding into other non-drug areas; Bristol-Myers shed its interests in those assets unrelated to the drug business (e.g., medical supply, nutritionals), focused on specialty drugs, and concentrated on only those therapeutic areas that it believed could be profitable over the long term. Its medicines help millions of people fight against such diseases as cancer, cardiovascular disease, hepatitis, HIV/ AIDS, and rheumatoid arthritis.



In 2016, one of Bristol-Myers’ lead immuno-oncology trials (CheckMate-026) failed and its stock price declined significantly. We think this is a short-term setback, and believe the company’s immuno-oncology business is particularly attractive with its strong pipeline of other drugs, significant growth potential, and reasonable valuation at 20 times forward earnings. After weighing the risks versus the long-term opportunities, we initiated a position in Bristol-Myers, which accounted for 1.3% of the Fund on December 31.





From Dodge & Cox's Stock Fund 2016 shareholder letter.



Check out Dodge & Cox latest stock trades

Baron Funds Comments on Bristol-Myers Squibb Co. - Oct 25, 2016

Bristol-Myers Squibb Company (NYSE:BMY) is a large diversified pharmaceutical company that is one of the leaders in the development of immune-system-stimulating therapies to fight cancer. These efforts are spearheaded by its product Opdivo, now approved to treat several types of cancer. After positive data was released on a rival drug to treat first-line advanced non-small-cell lung cancer, Bristol-Myers revealed that Opdivo did not meet the primary endpoint in a Phase III trial in the same indication, and its shares fell. We have exited our Bristol-Myers position, but are continuing to research the budding immuno-oncology space carefully. (Josh Riegelhaupt)







From Baron Opportunity Fund third-quarter 2016 commentary.



Check out Ron Baron latest stock trades

Baron Funds Comments on Bristol-Myers Squibb - May 23, 2016

After watching and following Bristol-Myers Squibb (NYSE:BMY) for the better part of the last three years we used the weakness in the stock created by the sell-off in the biotech sector to finally initiate a small to medium size position. Bristol specializes in small molecule drugs known as biologics, which are harder for the generic drug companies to replicate, and we are particularly excited about its lead immuno-oncology asset, Opdivo which has shown incredible promise in the treatment of lung cancer, while growing 10-20% month over month since its approval in 2015. Based on our belief in the effectiveness of the PD-1 class drugs, we think there is a high likelihood that Bristol will be able to gain approvals and expand the usage of Opdivo in other types of cancers (melanoma, renal, head and neck, hodgkin’s lymphoma, etc.) and could potentially change the paradigm of cancer’s treatment worldwide.



From Baron Fifth Avenue Growth Fund first quarter commentary 2016.



Check out Ron Baron latest stock trades

Baron Funds Comments on Bristol-Myers Squibb Company - May 06, 2016

After initiating a position in Bristol-Myers Squibb Company (NYSE:BMY), we increased our conviction in BMY’s stature as one of the premier names in all of biotech/pharma, deserving of its high multiple. Confidence comes from the performance of its lead immune-oncology asset, Opdivo that has captured 80–85% market share versus Merck’s competitive asset Keytruda, while growing 10–20% month over month. Given the frenetic pace of growth, we expect Opdivo to easily beat 2016’s $2.1 billion Consensus sales number. Looking past 2016, we expect this trend to continue as Bristol launches and/or expands usage of Opdivo in a variety of cancers (lung, melanoma, renal, head and neck, hodgkin’s lymphoma, etc.) and helps change the paradigm of cancer’s treatment worldwide.





From Baron Opportunity Fund first quarter 2016 commentary.







Check out Ron Baron latest stock trades

Top Ranked Articles about Bristol-Myers Squibb Company

Strong, Out-of-Favor Companies With Competitive Advantages Guru Mark Hillman is on the hunt for companies that have strong moats and have fallen out of favor with the market, or have value the market does not recognize
Why Emmaus Might Have Just Made Itself Attractive to Big Pharma How the company's latest development makes it a potential takeover target
If you would have mentioned the name Emmaus Life Sciences to an investor, even one familiar with the biotechnology space, a couple of months ago, chances are the said investor would not have had any idea who you were talking about. In fact, the same probably applies today. Read more...
Bristol-Myers Squibb and QIAGEN Sign Agreement for Use of NGS Technology to Develop Gene Expression Profiles for Immuno-Oncology Therapies
Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration
Dodge & Cox Buys Express Scripts, Bristol-Myers, HP The guru's largest 1st-quarter transactions
Dodge & Cox was founded in 1930 by Van Duyn Dodge and E. Morris Cox, and it manages a portfolio of 179 stocks. During the first quarter the guru traded shares in the following companies. Read more...
Top 5 Buys of Market-Beating Investors at Primecap Management Quiet managers have beat benchmark over long and short term
PRIMECAP Management (Trades, Portfolio)’s quiet nature belies its gravity-defying returns on long and short-term bases. Its best performer, the Primecap Fund, posted a 24.48% return for the year ended April 30, beating the 17.92% return in the S&P 500. It also outperformed on five-, 10- and since-inception categories. Read more...
Bristol-Myers Squibb and Calithera Biosciences Expand Collaboration Evaluating Opdivo (nivolumab) in Combination with CB-839 into Non-Small Cell Lung Cancer and Melanoma
David Tepper Invests Heavily in Pharma in 4th Quarter Guru gains 4 drug manufacturers, adds to Allergan
David Tepper (Trades, Portfolio), founder and president of Appaloosa Management, gained new holdings in pharmaceutical companies in the final quarter of 2016. Read more...
Baron Funds' Fifth Avenue Growth Fund Comments on Bristol-Myers Squibb Company Guru stock highlight
Bristol-Myers Squibb Company (NYSE:BMY) is a leading developer in Immuno-Oncology, the new wave of therapeutics aimed at displacing chemotherapeutics in cancer care with both improved efficacy (measured via survival outcomes) and safety profiles. While the class as a whole represents a success for society, the race for class dominance is heated and has proven to be difficult to predict. Coming into mid-2016, Bristol was the clear leader. The company squandered this lead in July when a widely anticipated clinical trial whose outcome was expected to read out positively, failed. While few question the drug’s efficacy, statistics and poor clinical trial design submarined Bristol and allowed competitor Merck to take the pole position commercially. Given the dire need for this patient population, the FDA granted Merck a pathway to market by the first half of this year that will give Merck at least a one year commercial advantage in time to market versus its competition. As a result, we decided to exit our investment in Bristol. While Merck has become the consensus leader, we think that their combination employs the wrong science approach and that Bristol is one of two players Read more...
Dodge & Cox Comments on Bristol-Myers Squibb Guru stock highlight
Once a diversified pharmaceutical company facing significant patent expirations (a “cliff”), Bristol-Myers (NYSE:BMY) has transitioned into a focused biopharmaceutical company that is positioned to grow. Many of its competitors responded to their patent cliffs by expanding into other non-drug areas; Bristol-Myers shed its interests in those assets unrelated to the drug business (e.g., medical supply, nutritionals), focused on specialty drugs, and concentrated on only those therapeutic areas that it believed could be profitable over the long term. Its medicines help millions of people fight against such diseases as cancer, cardiovascular disease, hepatitis, HIV/ AIDS, and rheumatoid arthritis. Read more...

Ratios

vs
industry
vs
history
PE Ratio 19.31
BMY's PE Ratio is ranked higher than
69% of the 555 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.93 vs. BMY: 19.31 )
Ranked among companies with meaningful PE Ratio only.
BMY' s PE Ratio Range Over the Past 10 Years
Min: 4.09  Med: 22.25 Max: 77.61
Current: 19.31
4.09
77.61
Forward PE Ratio 19.23
BMY's Forward PE Ratio is ranked lower than
51% of the 67 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 18.90 vs. BMY: 19.23 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 19.31
BMY's PE Ratio without NRI is ranked higher than
70% of the 554 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.21 vs. BMY: 19.31 )
Ranked among companies with meaningful PE Ratio without NRI only.
BMY' s PE Ratio without NRI Range Over the Past 10 Years
Min: 12.33  Med: 23.85 Max: 77.61
Current: 19.31
12.33
77.61
Price-to-Owner-Earnings 26.00
BMY's Price-to-Owner-Earnings is ranked higher than
61% of the 303 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.90 vs. BMY: 26.00 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
BMY' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 3.57  Med: 25.86 Max: 842.8
Current: 26
3.57
842.8
PB Ratio 6.36
BMY's PB Ratio is ranked lower than
83% of the 751 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.80 vs. BMY: 6.36 )
Ranked among companies with meaningful PB Ratio only.
BMY' s PB Ratio Range Over the Past 10 Years
Min: 2.46  Med: 4.87 Max: 8.51
Current: 6.36
2.46
8.51
PS Ratio 4.66
BMY's PS Ratio is ranked lower than
65% of the 736 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.97 vs. BMY: 4.66 )
Ranked among companies with meaningful PS Ratio only.
BMY' s PS Ratio Range Over the Past 10 Years
Min: 1.62  Med: 3.11 Max: 7.25
Current: 4.66
1.62
7.25
Price-to-Free-Cash-Flow 34.91
BMY's Price-to-Free-Cash-Flow is ranked lower than
63% of the 208 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.89 vs. BMY: 34.91 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
BMY' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.45  Med: 20 Max: 2406
Current: 34.91
7.45
2406
Price-to-Operating-Cash-Flow 23.68
BMY's Price-to-Operating-Cash-Flow is ranked lower than
59% of the 277 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.02 vs. BMY: 23.68 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
BMY' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.96  Med: 14.63 Max: 124.02
Current: 23.68
6.96
124.02
EV-to-EBIT 14.70
BMY's EV-to-EBIT is ranked higher than
68% of the 559 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.11 vs. BMY: 14.70 )
Ranked among companies with meaningful EV-to-EBIT only.
BMY' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.2  Med: 15.3 Max: 126.7
Current: 14.7
6.2
126.7
EV-to-EBITDA 13.63
BMY's EV-to-EBITDA is ranked higher than
63% of the 587 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.50 vs. BMY: 13.63 )
Ranked among companies with meaningful EV-to-EBITDA only.
BMY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.5  Med: 13.9 Max: 57.3
Current: 13.63
5.5
57.3
Shiller PE Ratio 24.27
BMY's Shiller PE Ratio is ranked higher than
76% of the 198 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 39.37 vs. BMY: 24.27 )
Ranked among companies with meaningful Shiller PE Ratio only.
BMY' s Shiller PE Ratio Range Over the Past 10 Years
Min: 10.83  Med: 16.92 Max: 36.54
Current: 24.27
10.83
36.54
Current Ratio 1.60
BMY's Current Ratio is ranked lower than
68% of the 782 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.40 vs. BMY: 1.60 )
Ranked among companies with meaningful Current Ratio only.
BMY' s Current Ratio Range Over the Past 10 Years
Min: 1.13  Med: 1.67 Max: 2.35
Current: 1.6
1.13
2.35
Quick Ratio 1.40
BMY's Quick Ratio is ranked lower than
61% of the 782 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.82 vs. BMY: 1.40 )
Ranked among companies with meaningful Quick Ratio only.
BMY' s Quick Ratio Range Over the Past 10 Years
Min: 0.93  Med: 1.39 Max: 2.06
Current: 1.4
0.93
2.06
Days Inventory 106.25
BMY's Days Inventory is ranked higher than
55% of the 707 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 117.36 vs. BMY: 106.25 )
Ranked among companies with meaningful Days Inventory only.
BMY' s Days Inventory Range Over the Past 10 Years
Min: 84.37  Med: 122.43 Max: 141.93
Current: 106.25
84.37
141.93
Days Sales Outstanding 74.65
BMY's Days Sales Outstanding is ranked higher than
51% of the 651 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 74.70 vs. BMY: 74.65 )
Ranked among companies with meaningful Days Sales Outstanding only.
BMY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 35.38  Med: 64.65 Max: 79.99
Current: 74.65
35.38
79.99
Days Payable 106.46
BMY's Days Payable is ranked higher than
72% of the 600 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 70.96 vs. BMY: 106.46 )
Ranked among companies with meaningful Days Payable only.
BMY' s Days Payable Range Over the Past 10 Years
Min: 84.65  Med: 141.65 Max: 230.86
Current: 106.46
84.65
230.86

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.79
BMY's Dividend Yield % is ranked higher than
77% of the 691 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.23 vs. BMY: 2.79 )
Ranked among companies with meaningful Dividend Yield % only.
BMY' s Dividend Yield % Range Over the Past 10 Years
Min: 1.99  Med: 3.98 Max: 7.07
Current: 2.79
1.99
7.07
Dividend Payout Ratio 0.53
BMY's Dividend Payout Ratio is ranked lower than
61% of the 406 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.33 vs. BMY: 0.53 )
Ranked among companies with meaningful Dividend Payout Ratio only.
BMY' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.53  Med: 0.92 Max: 1.6
Current: 0.53
0.53
1.6
3-Year Dividend Growth Rate 2.80
BMY's 3-Year Dividend Growth Rate is ranked lower than
62% of the 299 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.90 vs. BMY: 2.80 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
BMY' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 3.1 Max: 14.2
Current: 2.8
0
14.2
Forward Dividend Yield % 2.80
BMY's Forward Dividend Yield % is ranked higher than
76% of the 673 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. BMY: 2.80 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 3.20
BMY's 5-Year Yield-on-Cost % is ranked higher than
67% of the 821 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.11 vs. BMY: 3.20 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
BMY' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.28  Med: 4.57 Max: 8.12
Current: 3.2
2.28
8.12
3-Year Average Share Buyback Ratio -0.50
BMY's 3-Year Average Share Buyback Ratio is ranked higher than
73% of the 473 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.10 vs. BMY: -0.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BMY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -0.6  Med: 0.6 Max: 5.2
Current: -0.5
-0.6
5.2

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 14.63
BMY's Price-to-Tangible-Book is ranked lower than
90% of the 690 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.51 vs. BMY: 14.63 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
BMY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 4.16  Med: 12.04 Max: 53.46
Current: 14.63
4.16
53.46
Price-to-Intrinsic-Value-Projected-FCF 2.20
BMY's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
53% of the 328 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.31 vs. BMY: 2.20 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
BMY' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.13  Med: 1.77 Max: 4.89
Current: 2.2
1.13
4.89
Price-to-Median-PS-Value 1.50
BMY's Price-to-Median-PS-Value is ranked lower than
74% of the 712 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.09 vs. BMY: 1.50 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BMY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.62  Med: 0.95 Max: 2.76
Current: 1.5
0.62
2.76
Price-to-Graham-Number 3.54
BMY's Price-to-Graham-Number is ranked lower than
77% of the 480 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.08 vs. BMY: 3.54 )
Ranked among companies with meaningful Price-to-Graham-Number only.
BMY' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.53  Med: 3.1 Max: 15.06
Current: 3.54
1.53
15.06
Earnings Yield (Greenblatt) % 6.77
BMY's Earnings Yield (Greenblatt) % is ranked higher than
78% of the 805 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. BMY: 6.77 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BMY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.8  Med: 6.5 Max: 16.1
Current: 6.77
0.8
16.1
Forward Rate of Return (Yacktman) % 5.67
BMY's Forward Rate of Return (Yacktman) % is ranked lower than
60% of the 380 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.46 vs. BMY: 5.67 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
BMY' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -15.3  Med: 3.6 Max: 27
Current: 5.67
-15.3
27

More Statistics

Revenue (TTM) (Mil) $19,965.00
EPS (TTM) $ 2.88
Beta0.99
Short Percentage of Float0.51%
52-Week Range $46.01 - 76.80
Shares Outstanding (Mil)1,647.43

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 20,167 21,283 22,792
EPS ($) 2.87 3.17 3.63
EPS without NRI ($) 2.87 3.17 3.63
EPS Growth Rate
(Future 3Y To 5Y Estimate)
13.47%
Dividends per Share ($) 1.57 1.67 1.66
» More Articles for BMY

Headlines

Articles On GuruFocus.com
Strong Companies With Competitive Advantages — and Out of Favor Jul 17 2017 
Why Emmaus Might Have Just Made Itself Attractive to Big Pharma Jul 14 2017 
Bristol-Myers Squibb and QIAGEN Sign Agreement for Use of NGS Technology to Develop Gene Expression Jun 03 2017 
Portola Pharmaceuticals Could Be a Great June Trade Jun 02 2017 
Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration May 30 2017 
Dodge & Cox Buys Express Scripts, Bristol-Myers, HP May 25 2017 
Top 5 Buys of Market-Trouncing Firm Primecap Management May 19 2017 
Merck Collaborates With OncoSec Medical to Unlock Untapped Market for Keytruda May 10 2017 
Bristol-Myers Squibb and Calithera Biosciences Expand Collaboration Evaluating Opdivo (nivolumab) in May 10 2017 
Eaton Vance Worldwide Health Sciences Fund 1st Quarter Investment Report May 02 2017 

More From Other Websites
U.S. Food and Drug Administration Accepts Bristol-Myers Squibb’s Applications for Opdivo... Jul 24 2017
Ahead Of Earnings: Why You Should Be Buying Merck And Selling Bristol-Myers Jul 24 2017
Surprise in Store for Healthcare in Q2: Buy Top-Ranked ETFs Jul 24 2017
U.S. Food and Drug Administration Expands Approval of Yervoy® (ipilimumab) to Include Pediatric... Jul 24 2017
What's in the Offing for Bristol-Myers (BMY) in Q2 Earnings? Jul 21 2017
Amazon Snags Former Box Executive of Health In Pursuit of the Medical Industry Jul 20 2017
How Bristol-Meyers Squibb Has Benefited from Intangible Assets Jul 17 2017
Down 14.8%: Is Celldex Therapeutics Stock an Incredible Bargain? Jul 14 2017
AstraZeneca Pops On Report CEO Won't Jump Ship For Teva Pharma Jul 14 2017
Bristol-Myers Squibb Co. breached its 50 day moving average in a Bearish Manner : BMY-US : July 14,... Jul 14 2017
What Allergan’s Valuation as of July 13 Tells Us Jul 14 2017
Why Are Shares of Exelixis (EXEL) Up 77% So Far in 2017? Jul 13 2017
3 Dividend Stocks That Thrive in Market Crashes Jul 12 2017
3 Top Healthcare Stocks to Buy Today Jul 11 2017
Exelixis & Bristol-Myers Initiate Trial on Opdivo-Cabometyx Jul 11 2017
Bristol-Myers Squibb on the Street: Analyst Recommendations in July 2017 Jul 11 2017
Behind Bristol-Myer Squibb’s Virology Franchise Prospects Jul 11 2017
Why Bristol-Myers Squibb’s Empliciti Matters in 2017 Jul 11 2017
These 5 Cancer Drugs Will Be the Biggest Winners 5 Years From Now Jul 10 2017
How Bristol-Myers Squibb Stock Has Performed in 2Q17 Jul 10 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}